Surgalign Announces the Commercial Relaunch of its Next Generation CervAlign Anterior Cervical Plate System Optimized for Discectomy and Fusion Procedures
July 20 2022 - 7:30AM
Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical
technology company focused on elevating the standard of care by
driving the evolution of digital health, today announced the
commercial relaunch of its CervAlign® anterior cervical plate (ACP)
system. This next generation plate design comes with an enhanced
locking system design and enhances the Company’s position in one of
the largest procedural categories in spine—the anterior cervical
discectomy and fusion (ACDF) market.
“We are happy to introduce an improved version of CervAlign ACP
after an extended period of limited availability of one of our
flagship products,” stated Terry Rich, President and Chief
Executive Officer of Surgalign. “We took the past year to evaluate
the needs of the market and we are excited to bring the CervAlign
plate back as we continue to drive better patient outcomes. While
this ultimately hindered our 2021 results, it was the prudent move
and in the best interests of our customers and patients who rely on
our technology.”
The CervAlign system is designed for multiple ACDF procedural
solutions as it can accommodate semi-constrained, constrained and
hybrid constructs for one- to five-level anterior cervical fusions.
The plate features a 2.2mm minimum profile with zero-profile
locking designed to minimize tissue disruption and complications,
such as dysphasia.
“I am very pleased with the design of the next generation
CervAlign ACP system and am confident the new offering will lead to
improved clinical performance,” said Vittorio Morreale, MD, and
Director of Neurosurgery at Henry Ford Macomb Hospital in Michigan.
"The plate has a bolstered locking mechanism while retaining the
competitive low-profile design, and I believe it's a great solution
for my cervical patients."
Originally introduced to the market in 2019, the CervAlign
system was one of the Company’s fastest growing product lines. The
next generation plate design adds to the Company’s already robust
ACDF portfolio, which also includes Fortilink® interbody solutions
with TiPlus™ and TETRAfuse® technologies, Unison®-C standalone
interbody, and additional plating solutions. The anterior cervical
portfolio is complemented by the Company’s posterior cervical
solutions, which include Streamline® OCT, one of the lowest-profile
posterior cervical fixation systems on the market, and the Release®
laminoplasty system.
About Surgalign Holdings, Inc.Surgalign
Holdings, Inc. is a global medical technology company committed to
the promise of digital health to drive transformation across the
surgical landscape. Uniquely aligned and resourced to advance the
standard of care, the company is building technologies physicians
and other health providers will look to for what is truly possible
for their patients. Surgalign is focused on developing solutions
that predictably deliver superior clinical and economic outcomes.
Surgalign markets products throughout the United States and in more
than 50 countries worldwide through an expanding network of top
independent distributors. Surgalign is headquartered in Deerfield,
IL, with commercial, innovation and design centers in San Diego,
CA, Warsaw and Poznan, Poland, and Wurmlingen, Germany. Learn more
at www.surgalign.com and connect on LinkedIn and Twitter.
Forward Looking StatementThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on management’s current
expectations, estimates and projections about our products,
company, and industry, our management's beliefs, and certain
assumptions made by our management. Words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates,"
and other variations of such words and similar expressions are
intended to identify such forward-looking statements. These
statements are not guarantees of future performance and are subject
to risks and uncertainties, including the risks described in our
public filings with the U.S. Securities and Exchange Commission
(SEC). Our actual results may differ materially from the
anticipated results reflected in these forward-looking statements.
Copies of the company's SEC filings may be obtained by contacting
the company or the SEC or by visiting Surgalign's website
at www.surgalign.com or the SEC's website
at www.sec.gov.
Investor and Media Contact:Glenn
Wienergwiener@gwcco.com +1 917 887 8434 |
Surgalign Contact:Kristine
Simmonsksimmons@surgalign.com +1 619 206 4648 |
Surgalign (NASDAQ:SRGA)
Historical Stock Chart
From Apr 2024 to May 2024
Surgalign (NASDAQ:SRGA)
Historical Stock Chart
From May 2023 to May 2024